TORSEMIDE generics — when can they launch?
TORSEMIDE (TORSEMIDE) · · 2 active US patents · 0 expired
Where TORSEMIDE sits in the generic timeline
Long-dated protection: earliest active US patent for TORSEMIDE extends to 2033 (~7 years out). Generic competition is at least 4 years away. Lifecycle moves (new formulations, label extensions, combination filings) typically execute 18-36 months ahead of cliff.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Formulation — 2 patents
Sample patent estate
Showing 2 of 2 active US patents. View full estate on the TORSEMIDE drug page →
-
This patent protects controlled-release oral dosage formulations of Torsemide or a pharmaceutically acceptable salt thereof with specific sustained release excipients.USPTO title: Controlled-release formulations comprising Torsemide
-
This patent protects controlled-release oral dosage formulations of Torsemide or a pharmaceutically acceptable salt thereof with specific sustained release excipients.USPTO title: Controlled-release formulations comprising Torsemide
Sources
- FDA Orange Book — patents listed against TORSEMIDE (NDA filed 1993)
- TORSEMIDE drug profile — full patent estate, indications, clinical trials, pricing
- Patent cliff 2033 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on TORSEMIDE — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →